Replies to post #96 on Relmada Therapeutics Inc. (RLMD)

[VictorMasonIsRight]

Yes

But it’s all history, no impact on current RLMD prospects
Laidlaw did bring Honig who did buy 4.8mm shares at .80 in the 2014 PIPE:

https://ir.relmada.com/all-sec-filings/content/0001213900-14-007316/fs12014a2_relmada.htm#a_008

“Relmada’s (RLMD)drug, d-Meth, is a lot more potent and clean compared to dextromethorphan and should do better. It’s beneficial that more NMDA drugs show efficacy in depression to show that Relmada’s d-meth is clearly best in class.” ——Relmada CEO Dr. Sergio Traversa on the $2 billion appreciation of SAGE on news of their NMDA drug in phase 3 and AXSM's 100mm jump on phase 2 news on their NMDA drug

https://stockcharts.com/h-sc/ui?s=RLMD

https://www.sec.gov/Archives/edgar/data/1553643/000121390019000697/fs12019_relmadatherap.htm

https://www.marketwatch.com/press-release/10-q-relmada-therapeutics-inc-2018

[VictorMasonIsRight]

I predict REL1017 will be a billion dollar drug
based on SAGE and AXSM market appreciation based on phase 3 and phase 2 results.
$25/ share pre RS $100 after RS

Possibly a 2 billion dollar drug $50!